drugset / Trial / NCT00781430

Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease

NCT00781430

Phase 1 Completed 27 enrolled Puma Biotechnology, Inc.
Non-randomizedParallel-groupOpen-label

Summary

The purpose of this study is to assess the pharmacokinetics of neratinib and to assess the safety and tolerability of neratinib in healthy subjects and subjects with chronic liver disease.

Timeline

Start
2009-04
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Neratinib Small molecule 120 mg Oral

Indications